AbbVie's Rinvoq Gets a Big Win: Generics Delayed Until 2037!

AbbVie secured a "big win," delaying generic Rinvoq until April 2037 by settling lawsuits. This extends the drug's market run significantly, much longer than expected, boosting company value and helping offset declining Humira sales.